Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa, +25

The Lancet Oncology

MedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation Oncology +2

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, +126

The Lancet Oncology

MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology +3

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba, +27

New England Journal of Medicine

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal, +26

Journal of Clinical Oncology

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Sara Mainardi, Antonio Mulero‐Sánchez, Anirudh Prahallad, +11

Nature Medicine

MedicineCancer Cell BiologyBronchial NeoplasmCell BiologyCellular Biochemistry +7

A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

Juan Sandoval, Jesús Méndez‐González, Ernest Nadal, +28

Journal of Clinical Oncology

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, +20

Annals of Oncology

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah, Philippe A. Cassier, Salvatore Siena, +16

Nature Medicine

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes, +44

The Lancet Respiratory Medicine

Anti-pd-1 TreatmentMedicineRetrospective AnalysisCancer GenomicsBronchial Neoplasm +8

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Chiara Ambrogio, Gonzalo Goméz-López, Mattia Falcone, +14

Nature Medicine

Tumor BiologyMedicineTherapeutic StrategyKras-driven Lung AdenocarcinomaBronchial Neoplasm +9